ScholarIQanswers from OpenAlex
Institut Claudius Regaud
InstitutionResearch output, impact & collaborations
Institut Claudius Regaud is a institution indexed in ScholarIQ from OpenAlex.
What is known about Institut Claudius Regaud?
ScholarIQrecord summary
Institut Claudius Regaud is a research organisation in Toulouse, FR. OpenAlex records 5,221 works and 481,283 citations for it. 924 researchers list it as their most recent affiliation.
How many works does Institut Claudius Regaud have?
ScholarIQindexed works
Institut Claudius Regaud has 5,221 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Institut Claudius Regaud have?
ScholarIQcitation count
Institut Claudius Regaud has 481,283 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Institut Claudius Regaud?
ScholarIQresearcher count
Institut Claudius Regaud has 924 researchers in the ScholarIQ index.
What is the average h-index at Institut Claudius Regaud?
ScholarIQavg h-index
Institut Claudius Regaud has an average h-index of 73 in OpenAlex.
What is the ROR of Institut Claudius Regaud?
ScholarIQror
The ROR for Institut Claudius Regaud is on the source record.
What is the OpenAlex record for Institut Claudius Regaud?
ScholarIQopenalex
The OpenAlex for Institut Claudius Regaud is on the source record.
Who are the most-cited researchers behind Institut Claudius Regaud?
ScholarIQtop researchers by citations
What are the most-cited papers on Institut Claudius Regaud?
ScholarIQmost cited works
Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma
Arnaud Méjean, Alain Ravaud, Simon Thézenas, Sandra Colas, Jean‐Baptiste Beauval, Karim Bensalah, Lionnel Geoffrois, Antoine Thiery-Vuillemin, Luc Cormier, Hervé Lang, Laurent Guy, Gwénaëlle Gravis, Frédéric Rolland, Claude Linassier, É. Lechevallier, Christian Beisland, Michael Aitchison, Stéphane Oudard, Jean‐Jacques Patard, C Théodore, Christine Chevreau, Brigitte Laguerre, Jacques Hubert, Marine Gross‐Goupil, Jean‐Christophe Bernhard, Laurence Albigès, Marc‐Olivier Timsit, Thierry Lebrét, Bernard Escudier
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Thomas Powles, Piotr Tomczak, Se Hoon Park, Balaji Venugopal, Thomas Ferguson, Stefan N. Symeonides, Jaroslav Hájek, Howard Gurney, Yen‐Hwa Chang, Jae‐Lyun Lee, Naveed Sarwar, Antoine Thiery-Vuillemin, Marine Gross‐Goupil, Mauricio Mahave, Naomi B. Haas, Piotr Sawrycki, Joseph E. Burgents, Lei Xu, Kentaro Imai, David I. Quinn, Toni K. Choueiri, Piotr Tomczak, Toni K. Choueiri, Se Hoon Park, Balaji Venugopal, Thomas Ferguson, Jaroslav Hájek, Tzu-Ping Lin, Stefan N. Symeonides, Jae‐Lyun Lee, Piotr Sawrycki, Naomi B. Haas, Howard Gurney, Mauricio Mahave, Naveed Sarwar, Antoine Thiery-Vuillemin, Marine Gross‐Goupil, Christine Chevreau, John M. Burke, Gurjyot K. Doshi, Bohuslav Melichar, Delphine Topart, Stéphane Oudard, Evgeniy Kopyltsov, H. Hammers, David I. Quinn, Ajjai Alva, Juliana de Menezes, Adriano Gonçalves e Silva, Eric Winquist, Alketa Hamzaj, Giuseppe Procopio, Boguslawa Karaszewska, Ewa M. Nowakowska-Zajdel, B. Yа. Alekseev, Rustem Gafanov, А. А. Измайлов, Andrey Semenov, S. G. Afanasyev, Oleg Lipatov, T.B. Powles, Sandy Srinivas, David F. McDermott, Samith T. Kochuparambil, Ian D. Davis, Katriina Peltola, Roberto Sabbatini, Jinsoo Chung, М. I. Shkolnik, В. Б. Матвеев, P. Gajate Borau, Steven McCune, Thomas E. Hutson, Alejandro Dri, Silvio Correia Sales, Carrie Yeung, Carmen Marcela Alcala Castro, Peter J. Boström, Brigitte Laguerre, Consuelo Buttigliero, Ugo De Giorgi, Eugeniy A. Fomin, Yousef Zakharia, Clara Hwang, Eric A. Singer, Jeffrey T. Yorio, David Waterhouse, Rubén Dario Kowalyszyn, Margarita Sonia Alfie, Eduardo Yañez Ruiz, Tomáš Büchler, Krista Kankaanranta, G. Ferretti, Go Kimura, Kazuo Nishimura, Naoya Masumori, Satoshi Tamada, Haruaki Kato, Hiroshi Kitamura, Iwona Danielewicz
How much of the research on Institut Claudius Regaud is open access?
ScholarIQopen access share
50%OPEN ACCESS